May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy
November 7th 2022Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.
Read More
LIGHTHOUSE Study Further Confirms Benefit of Melphalan Flufenamide in R/R Multiple Myeloma
October 27th 2022Despite the small number of patients enrolled, the confirmatory phase 3 LIGHTHOUSE study of melphalan flufenamide in patients with relapsed/refractory multiple myeloma demonstrates promising safety and efficacy.
Read More
Roundtable Discussion: Zonder Reviews Choice of Therapy for R/R Multiple Myeloma
October 20th 2022During a Targeted Oncology case-based roundtable event, Jeffrey Zonder, MD, discussed with participants the later-line therapy options for patients who have relapsed following several lines of treatment for multiple myeloma.
Read More
Utilizing Immunotherapy Treatments and Managing Toxicities in Multiple Myeloma
October 15th 2022At a 2022 NCCN meeting, a panel discussed the use of immunotherapy for the treatment of patients with multiple myeloma, specifically how to choose the best course of action and how to manage toxicities.
Read More
The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma
October 5th 2022During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.
Read More
Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?
October 1st 2022Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.
Read More
CAR T-Cell Therapy Could Replace Auto Transplant in Multiple Myeloma
September 30th 2022The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.
Read More
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?
September 29th 2022With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Read More
ODAC Votes Against Melphalan Flufenamide in R/R Multiple Myeloma
September 22nd 2022Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.
Read More
Dara-KRd Leads to Encouraging Responses in Newly Diagnosed Multiple Myeloma
September 8th 2022The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities
Read More
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Read More